BR112014002669A2 - 5,6,7,8-tetra-hidro-6-[n,n-bis[(2-tienil)etil]]amino-1-naftol e método de preparação e uso do mesmo - Google Patents

5,6,7,8-tetra-hidro-6-[n,n-bis[(2-tienil)etil]]amino-1-naftol e método de preparação e uso do mesmo

Info

Publication number
BR112014002669A2
BR112014002669A2 BR112014002669A BR112014002669A BR112014002669A2 BR 112014002669 A2 BR112014002669 A2 BR 112014002669A2 BR 112014002669 A BR112014002669 A BR 112014002669A BR 112014002669 A BR112014002669 A BR 112014002669A BR 112014002669 A2 BR112014002669 A2 BR 112014002669A2
Authority
BR
Brazil
Prior art keywords
naphthol
tetrahydro
thienyl
bis
ethyl
Prior art date
Application number
BR112014002669A
Other languages
English (en)
Inventor
Zhou Fengmei
Yang Mina
Meng Qingguo
Wang Tao
Zhao Yanyan
Original Assignee
Shan Dong Luye Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shan Dong Luye Pharm Co Ltd filed Critical Shan Dong Luye Pharm Co Ltd
Publication of BR112014002669A2 publication Critical patent/BR112014002669A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8877—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

resumo patente de invenção: "5,6,7,8-tetra-hidro-6-[n,n-bis[(2-tienil)etil]] amino-1-naftol e método de preparação e uso do mesmo". a presente descrição refere-se ao 5,6,7,8-tetra-hidro-6-[n,n-bis[(2-tienil)etil]]amino-1-naftol, um método para preparação do mesmo, e ao uso de 5,6,7,8-tetra-hidro-6-[n,n-bis[(2-tienil)etil]]amino-1-naftol como um composto de referência para a determinação de uma impureza em rotigotina ou uma preparação da mesma.
BR112014002669A 2011-08-17 2012-08-06 5,6,7,8-tetra-hidro-6-[n,n-bis[(2-tienil)etil]]amino-1-naftol e método de preparação e uso do mesmo BR112014002669A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110235541 2011-08-17
PCT/CN2012/001038 WO2013023433A1 (en) 2011-08-17 2012-08-06 5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienyl)ethyl]]amino-1-naphthol, and preparing method and use thereof

Publications (1)

Publication Number Publication Date
BR112014002669A2 true BR112014002669A2 (pt) 2017-04-25

Family

ID=47714725

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002669A BR112014002669A2 (pt) 2011-08-17 2012-08-06 5,6,7,8-tetra-hidro-6-[n,n-bis[(2-tienil)etil]]amino-1-naftol e método de preparação e uso do mesmo

Country Status (12)

Country Link
US (1) US9012660B2 (pt)
EP (1) EP2744801B1 (pt)
JP (1) JP5986635B2 (pt)
KR (1) KR101798558B1 (pt)
CN (1) CN102952113B (pt)
AU (1) AU2012297492B2 (pt)
BR (1) BR112014002669A2 (pt)
CA (1) CA2842495C (pt)
ES (1) ES2625088T3 (pt)
PL (1) PL2744801T3 (pt)
RU (1) RU2609807C2 (pt)
WO (1) WO2013023433A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017082076A (ja) * 2015-10-27 2017-05-18 旭化成株式会社 ポリイソシアネート組成物、塗料組成物及び塗装方法
CN109580792A (zh) * 2017-09-28 2019-04-05 安徽省庆云医药股份有限公司 一种液相色谱法分离测定罗替戈汀及其光学异构体的方法
JP2022550299A (ja) * 2019-09-30 2022-12-01 シャンドン ルイ ファーマシューティカル カンパニー リミテッド 化合物及びその調製方法ならびにその使用
CN115326942B (zh) * 2022-02-22 2023-12-22 苏州正济医药研究有限公司 一种测定对甲苯磺酸噻吩酯的分析方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508453A1 (fr) * 1981-06-30 1982-12-31 Sanofi Sa Procede de preparation de derives des (thienyl-2)- et thienyl-3)-2 ethylamines et produits ainsi obtenus
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US20110313176A1 (en) * 2008-12-26 2011-12-22 Actavis Group Ptc Ehf Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
CN102010400B (zh) * 2009-09-07 2015-02-04 药源药物化学（上海）有限公司 S-5-取代-n-2'-(噻吩-2-基-)乙基-1,2,3,4-四氢萘-2-胺或其手性酸盐和用于制备罗替戈汀

Also Published As

Publication number Publication date
PL2744801T3 (pl) 2017-10-31
JP5986635B2 (ja) 2016-09-06
CN102952113A (zh) 2013-03-06
KR101798558B1 (ko) 2017-11-16
RU2014106825A (ru) 2015-08-27
CN102952113B (zh) 2013-10-09
AU2012297492B2 (en) 2015-09-24
AU2012297492A1 (en) 2014-02-06
CA2842495C (en) 2018-06-12
JP2014527524A (ja) 2014-10-16
WO2013023433A1 (en) 2013-02-21
EP2744801A1 (en) 2014-06-25
KR20140061404A (ko) 2014-05-21
CA2842495A1 (en) 2013-02-21
ES2625088T3 (es) 2017-07-18
EP2744801B1 (en) 2017-02-15
US20140196523A1 (en) 2014-07-17
RU2609807C2 (ru) 2017-02-06
US9012660B2 (en) 2015-04-21
EP2744801A4 (en) 2015-03-25

Similar Documents

Publication Publication Date Title
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BR112013023174A2 (pt) "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos"
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
BR112012027545A2 (pt) composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112013028959A2 (pt) composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112014002669A2 (pt) 5,6,7,8-tetra-hidro-6-[n,n-bis[(2-tienil)etil]]amino-1-naftol e método de preparação e uso do mesmo
BR112013020359B8 (pt) Colágeno gelificável e meios para a sua provisão
BR112013033861A2 (pt) composto, uso de um composto, composição farmacêutica, composição cosmética e uso cosmético de uma composição
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos
CR11755A (es) Dronedarona para la prevencion de la cardioversion
BR112013017184A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças
BR112014004437A2 (pt) composto, uso de um composto, composição farmacêutica, preparação farmacêutica, processo para preparação de um composto, e intermediário.
EP2759547A4 (en) PLATIN CONNECTION WITH AMINO OR ALKYLAMINE-CONTAINING AMMONIC ACID DERIVATIVES AS A SUBSTITUTE GROUP, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 333/20 , G01N 30/02

Ipc: C07D 333/20 (2006.01), G01N 30/02 (2006.01), A61P

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]